TaiMed Biologics (中裕新藥) announced today that its Phase 2b trial for the long-acting HIV antibody combination TMB-365/380 is ahead of schedule. The therapy is gaining significant traction with international potential partners due to its unique "No-Screening" advantage.

• Competitive Edge over Gilead: While Gilead’s long-acting combo (LEN+TAB+ZAB) offers six-month dosing, it requires patients to pass sensitivity tests for two Broadly Neutralizing Antibodies (bNAbs). This leads to a clinical exclusion rate of nearly 50%. TMB-365/380, however, requires no pre-screening, theoretically covering the entire patient population.
• Clinical Performance: Phase 2a data at Week 24 showed a 0% virologic failure (VF) rate, with 94% of subjects maintaining viral loads < 50 c/mL.
• Strategic Repositioning: TaiMed is shifting the product's focus from "late-line salvage therapy" to "first-line maintenance," aiming to expand its target market from 5% of the HIV population to the 50% of patients currently under viral suppression seeking better quality of life (e.g., lower injection site pain).

Resource:中裕TMB-365/380臨床2b進度超前，全球唯一「免篩選」優勢吸睛